SANTA FE, N.M.—A third clinical trial conducted by Helios CORP demonstrated its EstroG-100 ingredient positively effects women in various stages of menopause.
Evaluating 70 women, 10 of 12 symptoms significantly improved during a three-month period, or results duplicated the second clinical trial utilizing the same protocols (Kupperman Menopause Index, KMI).
These new findings added to a sound body of research, which includes two previous human clinical trials. The first double-blind placebo controlled trial using EstroG-100 showed six times better results in menopausal symptoms compared to the control group during a 12-month period, with no weight gain. The second human clinical trial found Estro-G100 significantly improved night sweats, hot flashes, vaginal dryness, insomnia, depression and joint discomfort in 61 menopausal participants over three months (also utilizing the KMI).
The third clinical trial focused on pre-, peri- and post-menopausal women, and it determined the oral supplementation of EstroG-100 can improve symptoms such as vasomotor, paresthesia (numbness or tingling), trouble sleeping, nervousness, melancholia, vertigo, fatigue, joint or muscle pain, headache, palpitation, formication (the sensation of crawling on the skin) and vaginal dryness.
Visit Helios CORP (booth 28125) at SupplySide West 2014 in Las Vegas to meet Jae Kim, EstroG-100’s inventor.